Effect of Febuxostat on Blood Pressure

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 121 participants.

Also called NCT01496469

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 121 participants (enrolled count) (from the registry)
Sponsor
  • Takeda Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01496469
  • WHO UTN U1111-1124-4638
Other papers using this trial's data
  • Effect of Febuxostat on Ambulatory Blood Pressure in Subjects With Hyperuricemia and Hypertension: A Phase 2 Randomized Placebo-Controlled Study Journal of the American Heart Association, 2017-11-04 DOI, PubMed 29102979, PMC5721765 In the PMC Open Access subset under CC BY-NC.

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01496469. Randomized; quadruple masking; primary purpose treatment. Start 2012-02 (registry gives no type); primary completion 2014-08 (actual). Results posted on 2015-08-31.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effect of Febuxostat on Blood Pressure
Condition
Hypertension
Intervention (Drug)
Febuxostat
Intervention (Drug)
Placebo
Lead sponsor
Takeda (class: industry)

Record details

Record id
cardio:ct-nct01496469
Content hash
74498a745ba45682376e8164685abce5a1ae6a2b41558fead996b9e85c38981e